Literature DB >> 23843840

Which Method is More Efficient in Determining Osteoporosis, QUS or DEXA?

Cem Dane1, Banu Dane.   

Abstract

Entities:  

Keywords:  Bone Mineral Density; Osteoporosis

Year:  2012        PMID: 23843840      PMCID: PMC3693636          DOI: 10.5812/ijem.5394

Source DB:  PubMed          Journal:  Int J Endocrinol Metab        ISSN: 1726-913X


× No keyword cloud information.
Dear Editor, We read with much interest the recently published article, “Effects of Raloxifene on Bone Metabolism in Hemodialysis Patients With Type 2 Diabetes,” by Saito et al (1). First, we would like to congratulate the authors. We wish to share a few scientific facts related to this interesting article. It was a pleasure to inform from this article that no difference was observed in BMD (bone mineral density) changes between patients with diabetes and nondiabetics after using raloxifene one year long. We have previously shown that the effects of low dose HRT and raloxifene on BMD at the lumbar spine and hip sites and biochemical markers of bone turnover in a randomized trial (2). In our study, the bone mineral density measurements with dual energy Xray absorptiometry (DEXA) method is accepted by the WHO as the gold standard for the diagnosis of osteoporosis. Satoi et al. proposed the SOS value has been shown to be significantly and positively correlated with lumbar BMD in the general population using methods such as DEXA in Patients and Methods section (1, 3). Quantitative calcaneal ultrasound has several potential advantages, including relatively low cost, no need for ionizing radiation, compact size, and ease of use. These advantages would make Quantitative calcaneal ultrasound an ideal screening tool if it can be shown to be an accurate indicator of skeletal density and fracture risk (4). The BMD measurement is accepted by the WHO as the gold standard for the diagnosis of osteoporosis. In another study, we have found a poor to moderate correlation between Quantitative ultrasound parameters (BUA, SOS, SI) and femoral and spinal BMD in pre and postmenopausal women (5). Tuna et al also reported, that the diagnostic value of tibial SOS did not seem to be high for discriminating between normal and low BMD at the femur and lumbar spine in postmenopausal women (6). I think that their results would be more precise if the authors’ preferred DEXA in spite of the measurement of calcaneal quantitative ultrasound parameters (SOS). We appreciate the authors and editor for publishing an important clinical article that may be beneficial to clinicians.
  6 in total

Review 1.  [CM-100].

Authors:  Hideaki Kishimoto
Journal:  Nihon Rinsho       Date:  2004-02

2.  Comparison of the effects of raloxifene and low-dose hormone replacement therapy on bone mineral density and bone turnover in the treatment of postmenopausal osteoporosis.

Authors:  Cem Dane; Banu Dane; Ahmet Cetin; Murat Erginbas
Journal:  Gynecol Endocrinol       Date:  2007-07       Impact factor: 2.260

3.  The role of quantitative ultrasound in predicting osteoporosis defined by dual-energy X-ray absorptiometry in pre- and postmenopausal women.

Authors:  C Dane; B Dane; A Cetin; M Erginbas
Journal:  Climacteric       Date:  2008-08       Impact factor: 3.005

4.  Does quantitative tibial ultrasound predict low bone mineral density defined by dual energy X-ray absorptiometry?

Authors:  Hakan Tuna; Murat Birtane; Galip Ekuklu; Fikret Cermik; Filiz Tuna; Siranus Kokino
Journal:  Yonsei Med J       Date:  2008-06-30       Impact factor: 2.759

5.  Effects of raloxifene on bone metabolism in hemodialysis patients with type 2 diabetes.

Authors:  Osamu Saito; Takako Saito; Shinji Asakura; Tetsu Akimoto; Makoto Inoue; Yasuhiro Ando; Shigeaki Muto; Eiji Kusano
Journal:  Int J Endocrinol Metab       Date:  2012-04-20

6.  Evaluation of calcaneal quantitative ultrasound in a primary care setting as a screening tool for osteoporosis in postmenopausal women.

Authors:  Adolfo Díez-Pérez; Fernando Marín; Joan Vila; Mercedes Abizanda; Artur Cervera; Cristina Carbonell; Rosa Ma Alcolea; Adoración Cama; Teresa Rama; Elena Galindo; Carmen Olmos
Journal:  J Clin Densitom       Date:  2003       Impact factor: 2.963

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.